Cell and gene therapy has long relied on plasmid DNA (pDNA) to power clinical innovation. But cell‑free DNA is already in use, treating patients, and rapidly becoming established as a scalable, consistent, and cost‑efficient alternative. As manufacturing demands grow, developers are reassessing which DNA format best supports speed, reliability, and future‑proofing.

Download this Q&A to get insights from Touchlight’s CSO Jill Makin, Ph.D., Chief Scientific Officer, on the advantages of cell-free DNA, and the considerations developers should make when selecting a platform.